Targeted mRNA for in vivo Reprogrammed Off-the-Shelf CAR-T Therapies
Time: 2:10 pm
day: Conference Day One
Details:
- Autologous CAR T cell products have been transformational in hematological malignancies; however, manufacturing complexities limit patient access
- Sanofi’s (Tidal) novel platform offers potential and promise of in vivo delivery of CARencoding mRNA as a novel therapeutics
- Transforming CAR-therapies by active in vivo reprogramming using novel targeted delivery approaches and advanced RNA therapeutic
